Biomarker Associated With Aggressive Breast Cancer Discovered
the Cancer Therapy Advisor take:
According to research published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers at Northwestern University have identified a biomarker strongly linked to basal-like breast cancer, a type of cancer that is resistant to various types of chemotherapy.
The biomarker is signal transducer and activator of transcription 3 (STAT3), a protein that has been previously identified and known to be overactive in numerous breast cancers.
Curt M. Horvath, PhD, of the Weinberg College of Arts and Sciences in Evanston, IL, and Robert W. Tell, PhD, of the Feinberg School of Medicine at Northwestern University in Chicago, IL, analyzed data from patients with luminal and basal-like breast cancers taken from the Cancer Genome Atlas. They found that certain genes were activated by STAT3 in basal-like breast cancers only.
Based on the results, Dr. Horvath says that a clinical study should be conducted to test a drug that inhibits the STAT3 protein from signaling cancer growth in patients with luminal and basal-like breast cancers; however, there are currently no available drugs that inhibit STAT3.
Basal-like breast carcinomas are highly aggressive and resistant to treatment because they are "triple-negative" tumors. They do not express estrogen or progesterone receptors or HER2 proteins. These types of cancer tend to have a high rate of mortality.
Scientists have identified a biomarker strongly associated with basal-like breast cancer.
Two Northwestern University scientists have identified a biomarker strongly associated with basal-like breast cancer, a highly aggressive carcinoma that is resistant to many types of chemotherapy.
The biomarker, a protein called STAT3, provides a smart target for new therapeutics designed to treat this often deadly cancer.
Using breast cancer patient data taken from The Cancer Genome Atlas, molecular biologists Curt M. Horvath and Robert W. Tell used powerful computational and bioinformatics techniques to detect patterns of gene expression in two cancer subtypes. They found that a small number of genes are activated by STAT3 protein signaling in basal-like breast cancers but not in luminal breast cancers.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro
- Age-adjusted Comorbidity Predicts Survival in Laryngeal Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Role of miR-125a-5p Clarified in Bladder Cancer